Relationship between IgG anti-B2GPI positivity and APS obstetric clinical manifestations
| . | . | . | . | . | . | Obstetric outcomes . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| First author (y) . | No. of participants . | No. of anti-B2GPI (+) . | Anti-B2GPI positivity cutoff . | No. of controls for assay calibration . | Length of follow-up . | Composite . | Fetal loss . | Preeclampsia/ eclampsia . | Placental abruption . | Intrauterine growth restriction . |
| Chauleur (2010) | 142 aPL(+) and 142 matched aPL(−) controls with history of embryonic loss | 47 IgG (+) 20 IgM (+) | 99th percentile | 200 | Duration of pregnancy through 3 mo postpartum | — | Not associated | aOR 4.61 | Trend (aOR 2.43, P = .07) | Not associated |
| Lockshin (2012) | 144 pregnant women with aPL positivity | 37 IgG (+) 22 IgM (+) | 25 units/mL (positive) 40 units/mL (high titer) | 60 | Duration of pregnancy and through 3 mo postpartum | Not associated | — | — | — | — |
| Lynch (1999) | 325 low-risk primigravida | NR | 50th percentile. Reported outcomes for 75th, 95th, and 99th percentile | NR | Duration of pregnancy | — | Not associated | Not associated | — | — |
| Yelnik (2016) | 54 aPL(+) pregnant women | 23 IgG (+) | 40 units/mL | 60 | Duration of pregnancy through 12 wk postpartum | Not associated | — | — | — | — |
| . | . | . | . | . | . | Obstetric outcomes . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| First author (y) . | No. of participants . | No. of anti-B2GPI (+) . | Anti-B2GPI positivity cutoff . | No. of controls for assay calibration . | Length of follow-up . | Composite . | Fetal loss . | Preeclampsia/ eclampsia . | Placental abruption . | Intrauterine growth restriction . |
| Chauleur (2010) | 142 aPL(+) and 142 matched aPL(−) controls with history of embryonic loss | 47 IgG (+) 20 IgM (+) | 99th percentile | 200 | Duration of pregnancy through 3 mo postpartum | — | Not associated | aOR 4.61 | Trend (aOR 2.43, P = .07) | Not associated |
| Lockshin (2012) | 144 pregnant women with aPL positivity | 37 IgG (+) 22 IgM (+) | 25 units/mL (positive) 40 units/mL (high titer) | 60 | Duration of pregnancy and through 3 mo postpartum | Not associated | — | — | — | — |
| Lynch (1999) | 325 low-risk primigravida | NR | 50th percentile. Reported outcomes for 75th, 95th, and 99th percentile | NR | Duration of pregnancy | — | Not associated | Not associated | — | — |
| Yelnik (2016) | 54 aPL(+) pregnant women | 23 IgG (+) | 40 units/mL | 60 | Duration of pregnancy through 12 wk postpartum | Not associated | — | — | — | — |
aOR, adjusted odds ratio; NR, not reported. Dashes denote outcomes that were not examined in a given study.